Formation of hepatic DNA adducts by methyleugenol in mouse models: Drastic decrease by Sult1a1 knockout and strong increase by transgenic human SULT1A1/2

Carcinogenesis

Volumn 35, Issue 4, 2014, Pages 935-941

  Herrmann, Kristin ^a   Engst, Wolfram ^a   Meinl, Walter ^a   Florian, Simone ^a   Cartus, Alexander T ^b   Schrenk, Dieter ^b   Appel, Klaus Erich ^c   Nolden, Tobias ^d,e   Himmelbauer, Heinz ^d,f   Glatt, Hansruedi ^a  

^a GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^b Rheinland Pfälzische Technische Universität Kaiserslautern Landau   (Germany)

^c FEDERAL INSTITUTE FOR RISK ASSESSMENT   (Germany)

^d MAX PLANCK INSTITUTE FOR MOLECULAR GENETICS   (Germany)

^e INSTITUTE OF MOLECULAR BIOLOGY   (Armenia)

^f CENTRE FOR GENOMIC REGULATION CRG   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

1' HYDROXYMETHYLEUGENOL; 3' HYDROXYMETHYLISOEUGENOL; ALKOXYBENZENE DERIVATIVE; DNA; METHYLEUGENOL; N2 (METHYLISOEUGENOL 3' YL) 2' DEOXYGUANOSINE; N6 (METHYLISOEUGENOL 3' YL) 2' DEOXYADENOSINE; NUCLEIC ACID; SULFOTRANSFERASE; SULFOTRANSFERASE 1A1; SULFOTRANSFERASE 1A2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; DNA ADDUCT; DOSE RESPONSE; EMBRYO; FEMALE; GENE INACTIVATION; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ARYLSULFOTRANSFERASE; BASE SEQUENCE; DNA ADDUCTS; DNA PRIMERS; DOSE-RESPONSE RELATIONSHIP, DRUG; EUGENOL; FEMALE; HUMANS; LIMIT OF DETECTION; LIVER; MALE; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; POLYMERASE CHAIN REACTION;

EID: 84894561504     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgt408     Document Type: Article

References (47)

1. De Vincenzi, M. et al. (2000) Constituents of aromatic plants: I. Methyleugenol. Fitoterapia, 71, 216-221.
2. Smith, B. et al. (2010) Application of the margin of exposure (MoE) approach to substances in food that are genotoxic and carcinogenic: example: methyleugenol, CASRN: 93-15-2. Food Chem. Toxicol., 48 (suppl. 1), 89-97.
3. European Union (2001) Opinion of the Scientific Committee on Food on Methyleugenol (4-Allyl-1,2-Dimethoxybenzene). http://ec.europa.eu/food/fs/sc/scf/out102_en.pdf (16 December 2013, date last accessed, document SCF/CS/FLAV/FLAVOUR/4 ADD1 FINAL).
4. Boberg, E.W. et al. (1983) Strong evidence from studies with brachymorphic mice and pentachlorophenol that 1′-sulfooxysafrole is the major ultimate electrophilic and carcinogenic metabolite of 1′-hydroxysafrole in mouse liver. Cancer Res., 43, 5163-5173.
5. NTP (2000) Toxicology and carcinogenesis studies of methyleugenol. Natl Toxicol. Program Tech. Rep. Ser., 491, 1-420.
6. Williams, G.M. et al. (2013) Methyleugenol hepatocellular cancer initiating effects in rat liver. Food Chem. Toxicol., 53, 187-196.
7. Innes, J.R.M. et al. (1969) Bioassay of pesticides and industrial chemicals for tumorigenicity in mice: a preliminary note. J. Natl Cancer Inst., 42, 1101-1114.
8. Long, E.L. et al. (1963) Liver tumors produced in rats by feeding safrole. Arch. Pathol., 75, 595-604.
9. Miller, E.C. et al. (1983) Structure-activity studies of the carcinogenicities in the mouse and rat of some naturally occurring and synthetic alkenylbenzene derivatives related to safrole and estragole. Cancer Res., 43, 1124-1134.
10. Randerath, K. et al. (1984) 32P-post-labelling analysis of DNA adducts formed in the livers of animals treated with safrole, estragole and other naturally-occurring alkenylbenzenes. I. Adult female CD-1 mice. Carcinogenesis, 5, 1613-1622.
11. Phillips, D.H. et al. (1984) 32P-post-labelling analysis of DNA adducts formed in the livers of animals treated with safrole, estragole and other naturally-occurring alkenylbenzenes. II. Newborn male B6C3F1 mice. Carcinogenesis, 5, 1623-1628.
12. Drinkwater, N.R. et al. (1976) Hepatocarcinogenicity of estragole (1-allyl-4-methoxybenzene) and 1′-hydroxyestragole in the mouse and mutagenicity of 1′-acetoxyestragole in bacteria. J. Natl Cancer Inst., 57, 1323-1331.
13. Wislocki, P.G. et al. (1977) Carcinogenic and mutagenic activities of safrole, 1′-hydroxysafrole, and some known or possible metabolites. Cancer Res., 37, 1883-1891.
14. Borchert, P. et al. (1973) 1′-Hydroxysafrole, a proximate carcinogenic metabolite of safrole in the rat and mouse. Cancer Res., 33, 590-600.
15. Chan, V.S.W. et al. (1992) Comparative induction of unscheduled DNA synthesis in cultured rat hepatocytes by allylbenzenes and their 1′-hydroxy metabolites. Food Chem. Toxicol., 30, 831-836.
16. Groh, I.A.M. et al. (2012) Genotoxic potential of methyleugenol and selected methyleugenol metabolites in cultured Chinese hamster V79 cells. Food Funct., 3, 428-436.
17. Schwartz, N.B. et al. (1978) Defective PAPS-synthesis in epiphyseal cartilage from brachymorphic mice. Biochem. Biophys. Res. Commun., 82, 173-178.
18. Boberg, E.W. et al. (1987) Inhibition by pentachlorophenol of the initiating and promoting activities of 1′-hydroxysafrole for the formation of enzymealtered foci and tumors in rat liver. Carcinogenesis, 8, 531-539.
19. Daimon, H. et al. (1997) Inhibition of sulfotransferase affecting in vivo genotoxicity and DNA adducts induced by safrole in rat liver. Teratog. Carcinog. Mutagen., 17, 327-337.
20. Herrmann, K. et al. (2012) Identification of human and murine sulfotransferases able to activate hydroxylated metabolites of methyleugenol to mutagens in Salmonella typhimurium and detection of associated DNA adducts using UPLC-MS/MS methods. Mutagenesis, 27, 453-462.
21. Riches, Z. et al. (2009) Quantitative evaluation of the expression and activity of five major sulfotransferases (SULTs) in human tissues: the SULT "pie". Drug Metab. Dispos., 37, 2255-2261.
22. Glatt, H.R. et al. (2001) Human cytosolic sulphotransferases: genetics, characteristics, toxicological aspects. Mutat. Res., 482, 27-40.
23. Blanchard, R.L. et al. (2004) A proposed nomenclature system for the cytosolic sulfotransferase (SULT) superfamily. Pharmacogenetics, 14, 199-211.
24. Schumacher, F. et al. (2012) Optimized enzymatic hydrolysis of DNA for LC-MS/MS analyses of adducts of 1-methoxy-3-indolylmethyl glucosinolate and methyleugenol. Anal. Biochem., 434, 4-11.
25. Herrmann, K. et al. (2013) Abundance of DNA adducts of methyleugenol, a rodent hepatocarcinogen, in human liver samples. Carcinogenesis, 34, 1025-1030.
26. Dobbernack, G. et al. (2011) Altered tissue distribution of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-DNA adducts in mice transgenic for human sulfotransferases 1A1 and 1A2. Carcinogenesis, 32, 1734-1740.
27. Cartus, A.T. et al. (2011) Metabolism of methylisoeugenol in liver microsomes of human, rat, and bovine origin. Drug Metab. Dispos., 39, 1727-1733.
28. Solheim, E. et al. (1976) Metabolism of alkenebenzene derivatives in the rat. II. Eugenol and isoeugenol methyl ethers. Xenobiotica, 6, 137-150.
29. Cartus, A.T. et al. (2012) Metabolism of methyleugenol in liver microsomes and primary hepatocytes: pattern of metabolites, cytotoxicity, and DNA-adduct formation. Toxicol. Sci., 129, 21-34.
30. Nagy, A. et al. (2002) Manipulating the Mouse Embryo: A Laboratory Manual. Cold Spring Harbor Laboratory Press, New York, NY.
31. Southern, E. (2006) Southern blotting. Nat. Protoc., 1, 518-525.
32. Gupta, K.P. et al. (1993) Formation and persistence of safrole-DNA adducts over a 10,000-fold dose range in mouse liver. Carcinogenesis, 14, 1517-1521.
33. Ruvinsky, A. et al. (2005) Mammalian Genomics. CABI Publishing, Oxfordshire, UK.
34. Mulder, G.J. et al. (1990) Sulfation. In Mulder, G.J. (ed.) Conjugation Reactions in Drug Metabolism: An Integrated Approach. Taylor and Francis, London, UK, pp. 107-162.
35. Anthony, A. et al. (1987) Metabolism of estragole in rat and mouse and influence of dose size on excretion of the proximate carcinogen 1′-hydroxyestragole. Food Chem. Toxicol., 25, 799-806.
36. Benedetti, M.S. et al. (1977) Absorption, metabolism and excretion of safrole in the rat and man. Toxicology, 7, 69-83.
37. Smith, R.L. et al. (2002) Safety assessment of allylalkoxybenzene derivatives used as flavouring substances: methyl eugenol and estragole. Food Chem. Toxicol., 40, 851-870.
38. Al-Subeihi, A.A. et al. (2012) Physiologically based kinetic modeling of bioactivation and detoxification of the alkenylbenzene methyleugenol in human as compared with rat. Toxicol. Appl. Pharmacol., 260, 271-284.
39. Mortelmans, K. et al. (1986) Salmonella mutagenicity tests: II. Results from the testing of 270 chemicals. Environ. Mutagen., 8 (suppl. 7), 1-119.
40. Sekizawa, J. et al. (1982) Genotoxicity of safrole-related chemicals in microbial test systems. Mutat. Res., 101, 127-140.
41. Glatt, H. (2000) Sulfotransferases in the bioactivation of xenobiotics. Chem. Biol. Interact., 129, 141-170.
42. Alnouti, Y. et al. (2006) Tissue distribution and ontogeny of sulfotransferase enzymes in mice. Toxicol. Sci., 93, 242-255.
43. Takahashi, S. et al. (2009) Molecular cloning, expression, and characterization of a novel mouse SULT6 cytosolic sulfotransferase. J. Biochem. 146, 399-405.
44. Fukami, T. et al. (2008) Structure and characterization of human carboxylesterase 1A1, 1A2, and 1A3 genes. Pharmacogenet. Genomics, 18, 911-920.
45. Hebbring, S.J. et al. (2007) Human SULT1A1 gene: copy number differences and functional implications. Hum. Mol. Genet., 16, 463-470.
46. Al-Subeihi, A.A. et al. (2011) Physiologically based biokinetic model of bioactivation and detoxification of the alkenylbenzene methyleugenol in rat. Toxicol. In Vitro, 25, 267-285.
47. Al-Subeihi, A.A. et al. (2013) Inhibition of methyleugenol bioactivation by the herb-based constituent nevadensin and prediction of possible in vivo consequences using physiologically based kinetic modeling. Food Chem. Toxicol., 59, 564-571.